Drug
Erfonrilimab clinical trials
Also written KN046.
- studies test it
- 20
- open now
- 6
- in phase 3
- 4
- first study started
- 2018
Keep track of what changes. Save the erfonrilimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- KN046
- 16
Combined with it in one product
Studies by the year they started
20 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 16
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 8
Jiangsu Alphamab Biopharmaceuticals Co., Ltd (8) · Peking University Cancer Hospital & Institute (4) · InxMed (Shanghai) Co., Ltd. (1) · Shanghai Zhongshan Hospital (1) · Suzhou Kintor Pharmaceutical Inc, (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · Weill Medical College of Cornell University (1)
Often tested with
Tested in the same studies.
Regorafenib (2) · Axitinib (2) · Lenvatinib (2) · Apatinib (1) · Concurrent Chemotherapy (1) · Anbenitamab (1) · Surufatinib (1) · Ascrinvacumab (1)
Studies
Open first, then newest update. How each study uses erfonrilimab is read from its arms, and is right about nine times in ten.
Testing it · 20
- IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerRecruitingPhase 1/2InxMed (Shanghai) Co., Ltd.NCT05827796Written as KN046
- Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerRecruitingPhase 1/2Shanghai Zhongshan HospitalNCT05832892Written as KN046
- A Phase Ib/II Study of GT90001 Combined With KN046 in Solid TumorsRecruitingPhase 1/2Suzhou Kintor Pharmaceutical Inc,NCT04984668Written as GT90001+KN046
- KN 046 Plus Regorafenib in MSS Metastatic Colorectal CancerRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT05985109Written as KN046
- The Efficacy and Safety of KN046 Combined With AxitinibRecruitingPhase 2/3Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06020352Written as KN046 plus Axitinib
- KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT05985707Written as KN046
- KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeActive, not recruitingPhase 2Peking University Cancer Hospital & InstituteNCT06099821Written as KN046
- Study of KN046 in Subjects With Advanced Non-Small Cell Lung CancerCompletedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05420220Written as KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
- A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal TumorsTerminatedPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04612712Written as KN046 Injection
- The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedPhase 2Peking University Cancer Hospital & InstituteNCT04542837Written as KN046
- A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint InhibitorsTerminatedPhase 2Weill Medical College of Cornell UniversityNCT04925947Written as KN046
- KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.Active, not recruitingPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05149326Written as KN046
- KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic CarcinomaTerminatedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04469725Written as KN046
- Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast CancerActive, not recruitingPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04165993Written as KN026 combination
- KN046 in Subjects With Advanced Solid Tumors and LymphomaCompletedPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03733951Written as KN046
- KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentTerminatedPhase 2/3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05001724Written as KN046
- KN046 in Subjects With Late Stage Esophageal Squamous Cell CarcinomaCompletedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03925870Written as KN046
- KN046 in Subjects With Advanced Squamous Non-small Cell Lung CancerStatus unknownPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04474119Written as KN046
- KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaStatus unknownPhase 2Shanghai Chest HospitalNCT03927495Written as KN046
- Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid TumorsStatus unknownPhase 1Alphamab (Australia) Co Pty Ltd.NCT03529526Written as KN046
Given in every arm · 4 — erfonrilimab is usual care beside what is tested
- Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GCRecruitingPhase 2Peking UniversityNCT06023758Written as KN046
- A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerCompletedPhase 1/2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03872791Written as KN046
- KN046 in Patients With Advanced Non-small Cell Lung CancerTerminatedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03838848Written as KN046
- Study of KN046 With Chemotherapy in First Line Advanced NSCLCStatus unknownPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04054531Written as KN046
Codes
What other systems call erfonrilimab · ClinicalTrials.gg INT015898
- UNII (FDA) 9NP50O6YSAERFONRILIMABOne source FDA
- NCI Thesaurus C157632ErfonrilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9NP50O6YSA | ERFONRILIMAB | One source FDA |
| NCI Thesaurus | C157632 | Erfonrilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.